← Back to Search

Vasodilator

Inhaled Nitric Oxide (iNO) for Liver Transplant

Phase 2
Waitlist Available
Led By Michael A Ramsay, MD
Research Sponsored by Baylor Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Liver Transplant
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This study is being done to determine if patients receiving (iNO) will have increased liver function and less damage from IR than patients who do not receive (iNO).

Eligible Conditions
  • Liver Transplant

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2014 Phase 2 trial • 124 Patients • NCT00955487
22%
Sepsis
8%
Necrotizing enterocolitis
5%
Threshold ROP
5%
Symptomatic PDA
3%
Severe ICH
100%
80%
60%
40%
20%
0%
Study treatment Arm
Inhaled Nitric Oxide (iNO)
Placebo (Nitrogen)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Placebo and StudyExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Inhaled Nitric Oxide (iNO)
2007
Completed Phase 2
~130

Find a Location

Who is running the clinical trial?

Baylor Research InstituteLead Sponsor
206 Previous Clinical Trials
203,423 Total Patients Enrolled
MallinckrodtIndustry Sponsor
201 Previous Clinical Trials
15,864 Total Patients Enrolled
Michael A Ramsay, MDPrincipal InvestigatorBaylor Health Care System
~0 spots leftby Nov 2025